ClinicalTrials.gg
CompletedNCT01987986Updated Oct 5, 2017Results posted

A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy

A Phase 2 interventional study of Collagenase Clostridium Histolyticum and Placebo in Edematous Fibrosclerotic Panniculopathy (EFP), sponsored by Endo Pharmaceuticals. Completed at 10 sites in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2017-10-05.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing Microbial Collagenase in Cellulite — none open to participants now, none under way, none of them phase 3. Microbial Collagenase · Cellulite.

Enrollment
8th of 15
150 · median 150
Started
2013
the only one that year
Phase 2
8 of 15
none open now
Registered
2nd of 15
by date
Lead sponsor
14 of 15
Endo Pharmaceuticals

Among the 15 studies testing Microbial Collagenase in Cellulite, this one is the 8th largest by enrollment, is the only one that started in 2013, is one of 8 in phase 2, and was the 2nd registered.

Cellulite

71 studies on the registry are indexed under Cellulite; 3 are open to participants now.

Browse Cellulite studies →

Open to participants now

None of the 15 studies testing Microbial Collagenase in Cellulite is open now. The open studies under Cellulite, anywhere →

Where they have run

About Microbial Collagenase

Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1 Cellulite study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing Microbial Collagenase in Cellulite as a file.
02

Study summary

To assess the safety and effectiveness of repeat doses of AA4500 in the treatment of edematous fibrosclerotic panniculopathy (EFP) commonly known as cellulite in adult women.

Read the detailed description

The Phase 2a study is a randomized, double-blind multiple-dose study that is expected to enroll approximately 144 women between the ages of 18 and 45 in the United States. Treatment effectiveness will be evaluated by investigator and patient assessments, as well as 3-D photographic imaging techniques. Once the safety and local tolerability profile from the first stage has been found to be acceptable subjects will be enrolled in stage 2. After an interim safety and local tolerability review was completed of all subjects in stage 1, it was determined that enrollment in stage 2 is acceptable and has been initiated.

03

Conditions studied

  • Edematous Fibrosclerotic Panniculopathy (EFP)

Browse trials for

Keywords

  • cellulite
  • dimple
  • orange peel
  • cottage cheese
  • mattress texture
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be a female between 18 to 45 years of age.
  2. Have at least one well defined dimple that is at least 1 cm but not more than 2 cm along the long axis and that is evident when the subject is standing
  3. Have a photonumeric cellulite severity scale (CSS) score between 6 and 12
  4. Have a (BMI) >19 and \<30 kg/m2, and intends to maintain stable body weight throughout the duration of the study
  5. Be willing to apply appropriate sunscreen to the selected quadrant before each exposure to the sun while participating in the study
  6. Be judged to be in good health, based upon the results of a medical history, physical examination, and laboratory profile at screening.
  7. Have a negative urine pregnancy test at screening and before injection of AA4500 and be using an effective method (ie, abstinence, intrauterine device [IUD], hormonal [estrogen/progestin] contraceptives, or barrier control) for at least one menstrual cycle prior to study enrollment and for the duration of the study.
  8. Be willing and able to cooperate with the requirements of the study.
  9. Voluntarily sign and date an agreement approved by the Institutional Review Board/Independent Ethics Committee/Human Research Ethics Committee (IRB/IEC/HREC).
  10. Be able to read, complete and understand the Patient Reported Outcomes rating instruments in English.

Exclusion criteria

Exclusion Criteria:

  1. Thyroid disease, unless controlled with medication for ≥ 6 months
  2. Uncontrolled diabetes mellitus, as determined by the investigator
  3. Uncontrolled hypertension, as determined by the investigator
  4. Vascular disorder (eg, phlebitis or varicose veins) in area to be treated
  5. Lipedema or a lymphatic disorder
  6. Cushing's disease and/or use of systemic
  7. History of lower extremity thrombosis or post-thrombosis syndrome
  8. Documented disorder such as lupus erythematosus, rheumatoid arthritis
  9. Inflammation or active infection in area to be treated
  10. Cutaneous alteration in area to be treated
  11. Rash, eczema, psoriasis, or skin cancer in the area to be treated
  12. History of keloidal scarring or abnormal wound healing
  13. Coagulation disorder
  14. Taking a medication for chronic anticoagulation (except for ≤ 150 mg aspirin daily)
  15. Known active hepatitis A, B or C
  16. Known immune deficiency disease or a positive test for (HIV)
  17. Other significant conditions including body dysmorphic disorder, which in the investigator's opinion would make the subject unsuitable for enrollment in the study
  18. Is menopausal defined as 12 months of amenorrhea in the absence of other biological or physiological causes, as determined by the investigator
  19. Has used any of the following for the treatment of EFP on the legs or buttock within the timelines identified below or intends to use any of the following at any time during the course of the study:

    • Liposuction on the side of the body selected for treatment during the 12-month period before injection of AA4500
    • Injections (eg, mesotherapy); radiofrequency device treatments; laser treatment; or surgery (including subcision) within the selected treatment quadrant during the 12-month period before injection of AA4500
    • Endermologie or similar treatments within the selected treatment quadrant during the 6-months period before injection of AA4500
    • Massage therapy within the selected treatment quadrant during the 3-month period before injection of AA4500
    • Creams (eg, Celluvera™, TriLastin®) to prevent or mitigate EFP within the selected treatment quadrant during the 2-week period before injection of AA4500
  20. Has a tattoo located within 2 cm of the site of injection
  21. Is presently nursing a baby or providing breast milk for a baby.
  22. Intends to become pregnant during the study.
  23. Intends to initiate an intensive sport or exercise program during the study.
  24. Has received an drug or treatment within 30 days before injection of AA4500.
  25. Has a known systemic allergy to collagenase or any other of AA4500.
  26. Has received any collagenase treatments within 30 days before treatment.

    -

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    AA4500 0.06 mg (low dose)

    AA4500 (Collagenase Clostridium Histolyticum) Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days.

    Biological: Collagenase Clostridium Histolyticum

  • Experimental
    AA4500 0.48 mg (mid-dose)

    AA4500 (Collagenase Clostridium Histolyticum) Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days.

    Biological: Collagenase Clostridium Histolyticum

  • Experimental
    AA4500 0.84 mg (high dose)

    AA4500 (Collagenase Clostridium Histolyticum) Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days.

    Biological: Collagenase Clostridium Histolyticum

  • Placebo comparator
    Placebo

    Placebo Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days.

    Biological: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Investigator Global Assessment of Aesthetic Improvement

    Investigators assessment of aesthetic improvement (I-GAIS) scores ranged from 3 to -1 as follows: 3 (very much improved), 2 (much improved), 1 (improved), 0 (no change), -1 (worse).

    Time frame: Baseline, Day 73

Other outcomes

  1. Investigator Cellulite Severity Score (CSS) Total Score- Change From Baseline

    The CSS is a photonumeric scale that was used to evaluate 5 morphologic features of cellulite; (A) number of evident depressions, (B) depth of depressions, (C) morphological appearance of skin surface alterations, (D) laxity, flaccidity or sagging of skin, and (E) current classification scale based on medical literature including Nuernberger and Mueller. The severity of each feature is rated on a scale from 0 (none) to 3 (most severe). The CSS total score is the sum of the 5 cellulite features (range: 0 to 15, with higher scores corresponding to more severe cellulite). Change is Day 73 study visit rating minus baseline rating; negative values indicate improvement in cellulite.

    Time frame: Baseline, Day 73

  2. Subject Cellulite Severity Item (CSI)-Change From Baseline

    CSI scores ranged from 0 (no cellulite present), 1 (very mild), 2 (mild), 3 (moderate), 4 (severe) to 5 (very severe). Change is Day 73 study visit rating minus baseline rating; negative values indicate a lessening in cellulite severity.

    Time frame: Baseline, Day 73

  3. Subject Global Bother Assessment (SGBA)- Change From Baseline

    Subjects rated their cellulite on a scale from 0 (not at all bothered) to 4 (extremely bothered). Change from baseline is Day 73 study visit value minus baseline value; negative change reflects an improvement in the amount the subject was bothered by cellulite; positive change reflects a worsening in the amount the subject is bothered by cellulite.

    Time frame: Baseline, Day 73

  4. Subject-reported Cellulite Impact Scale (SR-CIS)-Change From Baseline

    Subjects were asked to answer 6 exploratory questions regarding the appearance of their cellulite on a scale of 0 to 10 with 0 representing "not at all" and 10 representing "extremely." A SR-CIS total score was derived from these 6 questions with values varying from 0 (No negative impact) to 60 (Extreme negative impact). Change from baseline is Day 73 value minus baseline value; negative change reflects an improvement.

    Time frame: Baseline, Day 73

  5. Subject Satisfaction With Treatment Assessment (SCTA)

    Subjects rated their treatment satisfaction at the Day 73 visit on a 5-point scale ranging from -2 (very dissatisfied) to +2 (very satisfied)

    Time frame: Day 73

  6. Subject Global Assessment Cellulite (SGA-C)

    Subjects assessed their cellulite based on a 5-point scale from -1 (slightly worse), 0 (same), 1 (slightly improved), 2 (moderately improved), to 3 (much improved) on Day 73

    Time frame: Day 73

  7. Subject Global Assessment of Aesthetic Improvement (C-GAIS)

    Subjects's assessment of aesthetic improvement (C-GAIS) scores ranged from 3 to -1 as follows: 3 (very much improved), 2 (much improved), 1 (improved), 0 (no change), -1 (worse).

    Time frame: Day 73

07

Results

Posted Jul 2, 2017

Participant flow

Participant flow — Overall Study
MilestoneAA4500 0.06 mg (Low Dose)AA4500 0.48 mg (Mid-dose)AA4500 0.84 mg (High Dose)Placebo
Started43434024
Completed41433824
Not completed2020
Withdrew: Lost to follow-up1000
Withdrew: Adverse event1020

Outcome measures

PrimaryInvestigator Global Assessment of Aesthetic Improvement

Investigators assessment of aesthetic improvement (I-GAIS) scores ranged from 3 to -1 as follows: 3 (very much improved), 2 (much improved), 1 (improved), 0 (no change), -1 (worse).

Time frame:
Baseline, Day 73
Reported as:
Mean · units on a scale
Investigator Global Assessment of Aesthetic Improvement
units on a scaleAA4500 0.06 mg (Low Dose)AA4500 0.48 mg (Mid-dose)AA4500 0.84 mg (High Dose)Placebo
Investigator Global Assessment of Aesthetic Improvement0.7 ± 0.820.9 ± 0.931.1 ± 0.910.5 ± 0.72
Other pre-specifiedInvestigator Cellulite Severity Score (CSS) Total Score- Change From Baseline

The CSS is a photonumeric scale that was used to evaluate 5 morphologic features of cellulite; (A) number of evident depressions, (B) depth of depressions, (C) morphological appearance of skin surface alterations, (D) laxity, flaccidity or sagging of skin, and (E) current classification scale based on medical literature including Nuernberger and Mueller. The severity of each feature is rated on a scale from 0 (none) to 3 (most severe). The CSS total score is the sum of the 5 cellulite features (range: 0 to 15, with higher scores corresponding to more severe cellulite). Change is Day 73 study visit rating minus baseline rating; negative values indicate improvement in cellulite.

Time frame:
Baseline, Day 73
Reported as:
Mean · units on a scale
Investigator Cellulite Severity Score (CSS) Total Score- Change From Baseline
units on a scaleAA4500 0.06 mg (Low Dose)AA4500 0.48 mg (Mid-dose)AA4500 0.84 mg (High Dose)Placebo
Investigator Cellulite Severity Score (CSS) Total Score- Change From Baseline-1.1 ± 1.74-1.3 ± 1.70-1.9 ± 2.37-0.7 ± 1.52
Other pre-specifiedSubject Cellulite Severity Item (CSI)-Change From Baseline

CSI scores ranged from 0 (no cellulite present), 1 (very mild), 2 (mild), 3 (moderate), 4 (severe) to 5 (very severe). Change is Day 73 study visit rating minus baseline rating; negative values indicate a lessening in cellulite severity.

Time frame:
Baseline, Day 73
Reported as:
Mean · units on a scale
Subject Cellulite Severity Item (CSI)-Change From Baseline
units on a scaleAA4500 0.06 mg (Low Dose)AA4500 0.48 mg (Mid-dose)AA4500 0.84 mg (High Dose)Placebo
Subject Cellulite Severity Item (CSI)-Change From Baseline-0.7 ± 1.22-1.1 ± 1.07-1.3 ± 1.34-0.8 ± 1.35
Other pre-specifiedSubject Global Bother Assessment (SGBA)- Change From Baseline

Subjects rated their cellulite on a scale from 0 (not at all bothered) to 4 (extremely bothered). Change from baseline is Day 73 study visit value minus baseline value; negative change reflects an improvement in the amount the subject was bothered by cellulite; positive change reflects a worsening in the amount the subject is bothered by cellulite.

Time frame:
Baseline, Day 73
Reported as:
Mean · units on a scale
Subject Global Bother Assessment (SGBA)- Change From Baseline
units on a scaleAA4500 0.06 mg (Low Dose)AA4500 0.48 mg (Mid-dose)AA4500 0.84 mg (High Dose)Placebo
Subject Global Bother Assessment (SGBA)- Change From Baseline-0.9 ± 1.33-1.0 ± 1.23-1.0 ± 1.12-1.0 ± 1.33
Other pre-specifiedSubject-reported Cellulite Impact Scale (SR-CIS)-Change From Baseline

Subjects were asked to answer 6 exploratory questions regarding the appearance of their cellulite on a scale of 0 to 10 with 0 representing "not at all" and 10 representing "extremely." A SR-CIS total score was derived from these 6 questions with values varying from 0 (No negative impact) to 60 (Extreme negative impact). Change from baseline is Day 73 value minus baseline value; negative change reflects an improvement.

Time frame:
Baseline, Day 73
Reported as:
Mean · units on a scale
Subject-reported Cellulite Impact Scale (SR-CIS)-Change From Baseline
units on a scaleAA4500 0.06 mg (Low Dose)AA4500 0.48 mg (Mid-dose)AA4500 0.84 mg (High Dose)Placebo
Subject-reported Cellulite Impact Scale (SR-CIS)-Change From Baseline-15.0 ± 18.9-18.0 ± 15.70-17.7 ± 14.61-11.9 ± 13.97
Other pre-specifiedSubject Satisfaction With Treatment Assessment (SCTA)

Subjects rated their treatment satisfaction at the Day 73 visit on a 5-point scale ranging from -2 (very dissatisfied) to +2 (very satisfied)

Time frame:
Day 73
Reported as:
Mean · units on a scale
Subject Satisfaction With Treatment Assessment (SCTA)
units on a scaleAA4500 0.06 mg (Low Dose)AA4500 0.48 mg (Mid-dose)AA4500 0.84 mg (High Dose)Placebo
Subject Satisfaction With Treatment Assessment (SCTA)0.0 ± 1.310.9 ± 0.890.7 ± 0.930.1 ± 1.33
Other pre-specifiedSubject Global Assessment Cellulite (SGA-C)

Subjects assessed their cellulite based on a 5-point scale from -1 (slightly worse), 0 (same), 1 (slightly improved), 2 (moderately improved), to 3 (much improved) on Day 73

Time frame:
Day 73
Reported as:
Mean · units on a scale
Subject Global Assessment Cellulite (SGA-C)
units on a scaleAA4500 0.06 mg (Low Dose)AA4500 0.48 mg (Mid-dose)AA4500 0.84 mg (High Dose)Placebo
Subject Global Assessment Cellulite (SGA-C)0.9 ± 1.231.6 ± 0.851.5 ± 1.040.8 ± 0.96
Other pre-specifiedSubject Global Assessment of Aesthetic Improvement (C-GAIS)

Subjects's assessment of aesthetic improvement (C-GAIS) scores ranged from 3 to -1 as follows: 3 (very much improved), 2 (much improved), 1 (improved), 0 (no change), -1 (worse).

Time frame:
Day 73
Reported as:
Mean · units on a scale
Subject Global Assessment of Aesthetic Improvement (C-GAIS)
units on a scaleAA4500 0.06 mg (Low Dose)AA4500 0.48 mg (Mid-dose)AA4500 0.84 mg (High Dose)Placebo
Subject Global Assessment of Aesthetic Improvement (C-GAIS)0.9 ± 1.141.6 ± 0.881.4 ± 1.030.7 ± 0.91

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AA4500 0.06 mg (Low Dose)0/43 (0%)1/43 (2.3%)28/43 (65.1%)
AA4500 0.48 mg (Mid-dose)0/43 (0%)0/43 (0%)31/43 (72.1%)
AA4500 0.84 mg (High Dose)0/40 (0%)0/40 (0%)31/40 (77.5%)
Placebo0/24 (0%)0/24 (0%)7/24 (29.2%)
Most frequent serious events
Most frequent serious events
EventAA4500 0.06 mg (Low Dose)AA4500 0.48 mg (Mid-dose)AA4500 0.84 mg (High Dose)Placebo
Pharyngeal absessInfections and infestations1/430/430/400/24
Most frequent other events
Most frequent other events
EventAA4500 0.06 mg (Low Dose)AA4500 0.48 mg (Mid-dose)AA4500 0.84 mg (High Dose)Placebo
Injection site brusingGeneral disorders27/4330/4328/406/24
Injection site painGeneral disorders11/4318/4321/402/24
Injection site pruritusGeneral disorders0/435/437/400/24
Injection site swellingGeneral disorders3/437/435/400/24
Injection site discolorationGeneral disorders0/435/436/400/24
Injection site indurationGeneral disorders0/430/433/400/24
Injection site discomfortGeneral disorders0/430/432/400/24
Injection site haemorrhageGeneral disorders0/430/432/400/24
Injection site noduleGeneral disorders0/430/432/400/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)AA4500 0.06 mg (Low Dose)AA4500 0.48 mg (Mid-dose)AA4500 0.84 mg (High Dose)PlaceboTotal
Mean37.7 ± 5.7836.8 ± 7.0736.1 ± 5.6237.3 ± 8.0836.9 ± 6.50
Age, Customized
Age, Customized(Participants)AA4500 0.06 mg (Low Dose)AA4500 0.48 mg (Mid-dose)AA4500 0.84 mg (High Dose)PlaceboTotal
<2523218
25-3461112635
35-443323251394
>=45261413
Sex: Female, Male
Sex: Female, Male(Participants)AA4500 0.06 mg (Low Dose)AA4500 0.48 mg (Mid-dose)AA4500 0.84 mg (High Dose)PlaceboTotal
Female43434024150
Male00000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AA4500 0.06 mg (Low Dose)AA4500 0.48 mg (Mid-dose)AA4500 0.84 mg (High Dose)PlaceboTotal
Hispanic or Latino10139436
Not Hispanic or Latino33303120114
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AA4500 0.06 mg (Low Dose)AA4500 0.48 mg (Mid-dose)AA4500 0.84 mg (High Dose)PlaceboTotal
Asian00011
Black or African American234211
White40403620136
Other10012
Region of Enrollment
Region of Enrollment(participants)AA4500 0.06 mg (Low Dose)AA4500 0.48 mg (Mid-dose)AA4500 0.84 mg (High Dose)PlaceboTotal
United States43434024150
08

Study locations

10 sites
  • Dermatology Cosmetic Laser Medical Associates of La Jolla
    San Diego, California 92121, United States
  • ATS Clinical Research
    Santa Monica, California 90404, United States
  • Dermatology Research Institute
    Coral Gables, Florida 33146, United States
  • Kenneth Beer, MD PA
    West Palm Beach, Florida 33401, United States
  • Mercy Health Research
    Washington, Missouri 63090, United States
  • Sadick Research Group
    New York, New York 10075, United States
  • Stony Brook University Medical Center
    Stony Brook, New York 11794, United States
  • Tennessee Clinical Research Center
    Nashville, Tennessee 37215, United States
  • Charlottesville Dermatology
    Charlottesville, Virginia 22911, United States
  • Premier Clinical Research
    Spokane, Washington 99204, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 2 years 11 months after primary completion. A results delay was requested in Mar 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2013
First posted
Nov 20, 2013
Start
Oct 2013
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Results delay requested
Mar 17, 2015
Results first posted
Jul 2, 2017
Last update
Oct 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01987986
Responsible party
Sponsor
First posted
Nov 20, 2013
Start date
Oct 2013
Primary completion
Aug 2014
Completion
Aug 2014
Results posted
Jul 2, 2017
Last update
Oct 5, 2017

Study contacts

Veronica Urdaneta, MD MPH
study director · Endo Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion